ClearPoint Neuro, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Notes Payable (Details Narrative)

Notes Payable (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
Notes Payable (Details Narrative) - USD ($)	Apr. 04, 2017	Mar. 31, 2014	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016
Debt Instrument [Line Items]
Unamortized discount			$ 2,024,228
12% Junior Secured Notes Payable 2014 [Member] \| Private Placement (Securities Purchase Agreements) [Member]
Debt Instrument [Line Items]
Debt face amount		$ 3,725,000
Maturity period		5 years
Debt frequency of periodic payment		Semi-annually
Description of collateral terms		The 2014 Secured Notes are collateralized by a security interest in all of the Company’s assets, which security interest is junior and subordinate to the security interest that collateralizes the New Brainlab note.
Unamortized discount			67,770		$ 121,985
12% Junior Secured Notes Payable 2014 [Member] \| Private Placement (Securities Purchase Agreements) [Member] \| Non-Employee Directors [Member]
Debt Instrument [Line Items]
Debt face amount		$ 1,100,000
Other offering expenses			32,660		$ 58,789
12% Junior Secured Notes Payable 2014 [Member] \| Private Placement (Securities Purchase Agreements) [Member] \| Placement Agents [Member]
Debt Instrument [Line Items]
Fair value		30,210
Placement agents cash commission		145,500
Other offering expenses		$ 76,186
12% Junior Secured Notes Payable 2014 [Member] \| Private Placement (Securities Purchase Agreements) [Member] \| Warrant [Member]
Debt Instrument [Line Items]
Number of each common stock called		0.01
Proceeds from common stock called		$ 3,725,000
Warrant exercise price (in dollars per share)		$ 70.00
Fair value		$ 413,057
12% Junior Secured Notes Payable 2014 [Member] \| Private Placement (Securities Purchase Agreements) [Member] \| Warrant [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Number of common stock called		27,937
12% Junior Secured Notes Payable 2014 [Member] \| Private Placement (Securities Purchase Agreements) [Member] \| Warrant [Member] \| Placement Agents [Member]
Debt Instrument [Line Items]
Number of warrants issued to placement agent		1,818
Brainlab Senior Secured Note Payable [Member]
Debt Instrument [Line Items]
Stated interest rate				5.50%
Debt face amount				$ 5,000,000
Maturity date				Apr. 30, 2016
Accrued interest				$ 740,000
Brainlab Senior Secured Note Payable [Member] \| Securities Purchase Agreement (the "2016 PIPE Purchase Agreement") [Member]
Debt Instrument [Line Items]
Accrued interest			740,000
Debt cancelled principal amount			$ 1,300,000
Number of units issued			99,310
Gain on foregoing of debt			$ 941,000
Brainlab Senior Secured Note Payable [Member] \| 2016 Securities Purchase Agreement (Patent And Technology License Agreement) [Member]
Debt Instrument [Line Items]
Debt cancelled principal amount			$ 1,000,000
Brainlab Senior Secured Note Payable [Member] \| 2016 Securities Purchase Agreement (Patent And Technology License Agreement) [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Number of common shares issued			1
Brainlab Senior Secured Note Payable [Member] \| 2016 Securities Purchase Agreement (Patent And Technology License Agreement) [Member] \| 2016 Series A Warrants [Member]
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share)			$ 16.23
Number of common shares issued			0.4
Brainlab Senior Secured Note Payable [Member] \| 2016 Securities Purchase Agreement (Patent And Technology License Agreement) [Member] \| 2016 Series B Warrants [Member]
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share)			$ 21.10
Number of common shares issued			0.3
New Brainlab Note (amended and restated secured note) [Member] \| Securities Purchase Agreement (the "2016 PIPE Purchase Agreement") [Member]
Debt Instrument [Line Items]
Debt face amount	$ 2,000,000
Maturity date	Dec. 31, 2018
Description of collateral terms	Note is collateralized by a senior security interest in all of the assets of the Company.